Function Health Pricing History and Trajectory: What Members Actually Pay

What Is Function Health and How Does Its Business Model Work?

Function Health is a direct-to-consumer lab-testing subscription. Members pay an annual fee, schedule blood draws at Quest Diagnostics locations, and receive results through the company's web platform alongside brief clinician commentary on out-of-range values. The company does not provide ongoing physician care, does not prescribe medications directly through the core membership, and is not a licensed clinical laboratory. It contracts with Quest, which holds CLIA certification under 42 CFR Part 493. CLIA regulatory requirements for clinical laboratories are maintained by CMS.

The longevity-lab market Function Health entered is not regulated the way pharmaceutical drugs are. The FDA regulates laboratory-developed tests under enforcement discretion rules that shifted meaningfully in 2024, when the agency finalized a rule asserting oversight authority over LDTs. The FDA's 2024 final rule on laboratory-developed tests is available at FDA.gov. That regulatory context matters when evaluating any direct-to-consumer lab company's claims about what its panels detect.

Who Founded the Company

Function Health was co-founded by Jonathan Swerdlin and Dr. Mark Hyman, the latter a well-known functional-medicine author and former director of Cleveland Clinic's Center for Functional Medicine. Dr. Hyman's clinical background is family medicine. The Cleveland Clinic Center for Functional Medicine is described on the institution's own pages, though Dr. Hyman departed that role before Function Health launched.

Revenue Model and Growth

The company is venture-backed. It raised a reported $52 million Series A in 2023. Subscription revenue scales directly with member count, which creates pressure to grow the member base and, over time, to increase per-member revenue through price increases or upsell tiers. Both have occurred.

Function Health Pricing History: A Year-by-Year Breakdown

Function Health has raised its price twice in roughly 30 months of operation. The trajectory is upward, with no publicly announced cap.

2023: $499 Launch Price

The company launched publicly in early 2023 at $499 per year. Early adopters who joined during the waitlist phase were sometimes quoted $399. Those grandfathered rates were not guaranteed to persist at renewal, and member reports on Reddit's r/longevity and r/functionhealth communities indicate most early members saw their renewal price shift to the standard tier within 12 to 18 months.

At $499, the pitch was straightforward: Quest Diagnostics' retail cash-pay price for a comprehensive metabolic panel runs roughly $30 to $50, a lipid panel $25 to $40, a thyroid panel (TSH plus free T3 and free T4) $60 to $90, and a hemoglobin A1c around $30. Quest Diagnostics publishes some consumer pricing through its MyQuestDiagnostics portal, though prices vary by region. Stacking 100-plus individual tests at retail rates would cost several thousand dollars, so the bundle appeared favorable at launch.

2024: Standard Tier Raised to $599

By the fourth quarter of 2024, Function Health had raised its standard annual membership to $599. The company did not publish a formal press release announcing the increase. Members discovered it at renewal. Complaints logged with the Better Business Bureau during this period frequently cited surprise at the price jump and difficulty obtaining refunds after the draw had already occurred. The BBB's profile for Function Health shows the company is not BBB accredited and lists open complaints as of the most recent review.

A $100 per year increase on a $499 base is a 20% hike. For context, U.S. General consumer inflation (CPI) ran approximately 3.4% in 2024 per BLS data published on the Bureau of Labor Statistics website. The Function Health price increase outpaced general inflation by roughly 6x in that single year.

2025: Advanced Tier at $1,199

In early 2025, Function Health introduced an "Advanced" membership at $1,199 per year. This tier adds additional biomarkers, including some hormone panels, heavy metals, and expanded cancer-screening markers such as the Galleri multi-cancer early detection test from GRAIL. GRAIL's Galleri test received Breakthrough Device designation from the FDA, though it has not received FDA clearance or approval as a standalone diagnostic and should not be used as a replacement for standard cancer screening per current USPSTF guidelines. The USPSTF maintains its screening recommendations at uspreventiveservicestaskforce.org.

The table below summarizes the pricing trajectory:

| Year | Tier | Annual Price | Key Additions | |------|------|-------------|---------------| | 2023 | Standard (launch) | $499 | ~100 biomarkers, Quest draw | | 2024 | Standard | $599 | Minimal panel changes noted publicly | | 2025 | Standard | $599 | Unchanged | | 2025 | Advanced | $1,199 | Galleri, hormones, heavy metals |

Is Function Health Legit? Regulatory and Credential Check

"Legit" means different things depending on what you are evaluating. The labs themselves are processed by Quest Diagnostics, a CLIA-certified laboratory. The results are real. The question is whether the clinical oversight layer Function Health adds justifies the subscription cost, and whether the marketing claims are proportionate to what the service actually provides.

CLIA, Quest, and Lab Accuracy

Quest Diagnostics operates under CLIA certification, which is the federal standard for clinical laboratory quality under the Clinical Laboratory Improvement Amendments of 1988. CMS oversees CLIA certification and publishes the regulatory framework at cms.gov. Function Health does not run its own laboratory. It acts as a requisitioning entity that orders labs through Quest on members' behalf. This is a legal and common arrangement, used by many direct-to-consumer lab companies including Ulta Lab Tests and LabCorp's consumer portal.

Physician Oversight: What It Actually Includes

The standard membership provides clinician review of out-of-range values via an asynchronous platform message. Members do not receive a scheduled physician consultation. They receive a brief note. If a result is critically abnormal, Function Health states it will contact the member directly. This is materially different from an ongoing physician-patient relationship and does not constitute a diagnosis or a treatment plan. The American Medical Association's ethical guidance on telehealth relationships distinguishes between asynchronous review services and established clinical relationships.

Patients who receive unexpected findings through Function Health (for example, an elevated PSA or an abnormal thyroid-stimulating hormone) still need to follow up with a licensed physician who can order imaging, perform a physical examination, and initiate treatment. The platform does not replace that step.

LegitScript and Pharmacy Verification

LegitScript is an independent verification service that classifies online health companies as certified, rogue, or not-applicable. LegitScript's certification program is described at legitscript.com. Function Health does not appear in LegitScript's verified telehealth or pharmacy databases as of mid-2025. This does not mean the company is fraudulent. Function Health does not primarily operate as a pharmacy, so LegitScript's pharmacy certification framework may not apply directly. The absence from that database is worth noting for consumers who use LegitScript as a due-diligence tool.

State Medical Board Considerations

Telehealth companies that provide clinical services across state lines must comply with state-specific medical practice acts. Function Health's physician-review model has not, as of this writing, resulted in published state medical board disciplinary actions. Consumers can verify this through their own state's medical board directory. The Federation of State Medical Boards maintains a directory of state board websites at fsmb.org.

Function Health Complaints: Common Patterns

Complaints about Function Health cluster into three categories based on BBB filings, Trustpilot reviews, and community forums as of mid-2025.

Billing and Refund Disputes

The most common complaint type involves billing. Members who pay for the annual membership and then cannot schedule a draw within their region (Quest locations are not uniformly available), or who have a draw canceled, report difficulty obtaining refunds. Function Health's published refund policy states that refunds are not available after a blood draw has occurred and are only available before the first draw on a case-by-case basis. This policy is stricter than many subscription-health services.

One pattern that appears repeatedly in BBB complaints: members charged at renewal at a higher price than their original membership, without a clear advance notice of the rate change. A 30-day written notice of price increases is a standard consumer-protection practice; the specifics of Function Health's notification practices are not publicly disclosed in their member agreement terms as of the last review.

Clinical Adequacy Concerns

A second category involves members who received abnormal results and felt the platform's guidance was insufficient. Receiving a flagged ApoB level or an elevated ferritin without access to a clinician who can contextualize the result in your full medical history is a real limitation of the model. The American College of Cardiology's guidance on ApoB as a cardiovascular risk marker is published at acc.org, and that guidance emphasizes clinical interpretation alongside other risk factors, not standalone lab values. Cardiovascular risk factor assessment guidelines from the American Heart Association underscore the same principle.

Customer Service Response Time

A third pattern involves slow or automated customer-service responses to billing and clinical questions. This is common among venture-backed health startups scaling faster than their support infrastructure. It does not indicate fraud, but it does affect member experience and is relevant to value assessment at $599 to $1,199 per year.

How Function Health Pricing Compares to Alternatives

Knowing the trajectory of Function Health's pricing is more useful when set against direct competitors.

Direct Competitors

Marek Health offers physician-supervised lab panels with actual follow-up consultations starting around $150 to $300 per panel depending on comprehensiveness. InsideTracker charges $699 per year for its "Ultimate" tier with 43 biomarkers, fewer than Function Health's panel count but with a more structured optimization framework. Ulta Lab Tests and Any Lab Test Now allow a la carte ordering at Quest or LabCorp; a thoughtfully selected panel of 40 to 50 tests commonly runs $200 to $400 annually without any subscription fee.

Walk-In Lab publishes retail cash-pay prices for individual Quest and LabCorp tests. Walk-In Lab's pricing is available at walkinlab.com, and a broad longevity panel assembled from their menu commonly comes to $300 to $500 with no annual commitment.

The Insurance Angle

Many of the biomarkers in Function Health's panel, including fasting glucose, HbA1c, lipid panels, CBC, CMP, and TSH, are covered by most major insurance plans when ordered by a primary care physician as part of an annual wellness visit. The USPSTF recommends screening for type 2 diabetes in adults aged 35 to 70 who are overweight or obese, and that recommendation means the test is covered without cost-sharing under the ACA's preventive care provisions. The ACA's preventive services requirement is described at healthcare.gov. Patients with a functioning primary care relationship may already receive many of Function Health's core tests at no out-of-pocket cost.

Value Analysis: Is the Price Justified?

The honest answer is: it depends on your baseline access to care.

When Function Health May Be Worth the Cost

For patients without a primary care physician, without insurance, or in regions where specialist access is limited, Function Health's $599 standard tier could provide a reasonable breadth of data points at a lower cost than assembling the equivalent tests through retail channels. Someone without health insurance who wants an annual metabolic, hormonal, and cardiovascular snapshot would likely pay $1,500 to $3,000 for equivalent Quest retail tests ordered without a bundled subscription. National survey data from the CDC's National Health Interview Survey documents that roughly 8% of U.S. Adults under 65 remain uninsured, representing a real market for cash-pay lab bundles.

When It Is Unlikely to Be Worth the Cost

If you have insurance and an engaged primary care physician, the core value proposition weakens substantially. You are paying $599 to $1,199 per year primarily for convenience and access to a branded dashboard. The clinical oversight is minimal. The Galleri multi-cancer detection test in the Advanced tier is not FDA-approved and is not recommended by the USPSTF or the American Cancer Society as a standard screening tool. The American Cancer Society's position on multi-cancer early detection tests is summarized at cancer.org, noting that evidence for population-level mortality benefit remains under evaluation in ongoing trials such as the NHS-Galleri trial (N=140,000), which had not reported primary outcomes as of this writing.

Price Trajectory Risk

Three data points do not make a trend, but the trajectory, $499 in 2023, $599 in 2024 to 2025 standard, and $1,199 for the new Advanced tier, suggests Function Health is moving toward higher annual costs. Members who join at $599 should factor in a reasonable probability of renewal at $699 to $799 within 24 months, based on the rate of prior increases.

What the Medical Literature Says About Broad Lab Screening in Healthy Adults

Function Health's marketing leans heavily on the premise that broad proactive testing improves health outcomes. The evidence base for this in asymptomatic healthy adults is more limited than the marketing implies.

Screening Yield in Low-Risk Populations

A 2019 Cochrane review of general health checks (comprehensive screening of asymptomatic adults) found no statistically significant reduction in all-cause mortality, cardiovascular mortality, or cancer mortality in the intervention groups compared to controls. The Cochrane review by Krogsboll et al. Is available through the Cochrane Library. That finding does not mean testing is useless. It means broad undifferentiated testing of healthy people does not, by itself, reduce mortality without downstream clinical action.

The USPSTF's evidence-based screening recommendations are built on this kind of systematic review. The USPSTF's methodology is described on their site. Tests that Function Health includes but that lack a USPSTF Grade A or B recommendation for general-population screening should be interpreted cautiously. Elevated results on non-validated screening tests can generate anxiety, additional testing, and downstream costs without improving outcomes, a phenomenon documented in screening-harm literature. The New England Journal of Medicine published a detailed analysis of overdiagnosis in cancer screening in 2022, noting that overdiagnosis rates in some cancer screening programs reach 15% to 25%.

When Comprehensive Labs Do Add Value

Comprehensive metabolic and hormonal panels do add clinical value in specific populations: adults with diabetes or prediabetes, those with thyroid disease, those on lipid-lowering therapy, men on testosterone-replacement therapy, and women approaching or in perimenopause. The American Diabetes Association's Standards of Care recommend HbA1c testing every 3 months for patients not at goal, and annually for stable patients. The Endocrine Society's clinical guidelines on male hypogonadism recommend monitoring total testosterone, hematocrit, and PSA at 3 and 6 months after initiating TRT, then annually. For these populations, Function Health's bundle may align with medically indicated monitoring.